Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Zhi Chen

Shawn David Erickson

Eric Mertz

Yimin Qian

Elbert Chin

Christine E Brotherton-Pleiss

Stephen Deems Gabriel

Robert James Weikert

Sung-Sau So

Jean-Marc Plancher

Peter Michael Wovkulich

Qingjie Ding

Kyungjin Kim

Hongju Li

Buelent Kocer

Lin Yi

Joseph Anthony Bilotta

Feng Chi

Joseph P Lyssikatos

Anthony A Estrada

Huifen Chen

Allen John Lovey

Shaoqing Chen

Jing Zhang

Steven Joseph Berthel

Nan Jiang

Qiang Zhang

David Shawn Erickson

Robert J Weikert

Han Ma

Klaus Klumpp

The present invention discloses compounds of Formula I wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection. 

Antiviral compounds

The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection. 

The invention is concerned with the compounds of formula (I): and salts thereof, wherein X, Y, Z, R, R, R, R, R, Rand Rare defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of Formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Substituted sulfonamide compounds

The present invention discloses compounds of Formula (I): wherein the variables in Formula (I) are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula (I) in the prevention or treatment of HCV infection. 

The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.

The invention is concerned with the compounds of formula (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) can be used as medicament.

6-aminoindole derivatives as TRP channel antagonists

The invention is concerned with a compound of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R3, X and Y are as defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

Acetamide derivatives

The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Y, R1, R2 and R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists of the TRPA1 channel and may be useful in treating inflammatory diseases and disorders associated with that channel.

Substituted phenylcarbamate compounds

Growing community of inventors

Livingston, NJ, United States of America

Zhi Chen